IN VIVO Blog started up in earnest about eight months ago, and in that time we've racked up hundreds of posts covering a wide variety of topics, like Big Pharma's pipeline troubles, biotech exit strategies, financing, drug regulation, managment succession, and the Philadelphia sports scene. But, you're wondering, what are our favorites? Well, reader, wait no longer. Because to jumpstart your workayear life we've completely unscientifically collected our Top Ten posts of 2007.
9. RNAi: We broke the news about the next-generation RNA interference company Dicerna, and followed up with news of its Series A & new competition from Nastech spin-out MDRNA. We also covered Alnylam's spectacular platform deal with Roche and AZ/Silence's smaller but important-to-the-biotech alliance.
6. Diagnosis Negative: Icahn wasn't the only party rebuffed. Roche spent most of the year getting turned down by Ventana, which played down the pharma's $3 billion offer multiple times. First they said please, then highlighted its belief in the importance of its diagnostics business by promoting its dx head Severin Schwann to CEO of the whole Roche Group. We suggested soon thereafter that Ventana should do the deal, and in late November they indeed decided to at least think harder about it.
3. Capital Connections: IN VIVO Blog would be less informative and well rounded without our colleagues from The RPM Report, who've written some brilliant posts regarding regulation and policy (not to mention biotech CEO entourages). Lets start with FDA and CMS teaming up against erythropoietin marketers J&J and Amgen, and our series of posts on the subject. And then there's our coverage of the Avandia situation, FDA's leadership, and drug safety.